Aytu BioPharma, Inc.
AYTU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $18 | $15 | $7 | $10 |
| - Cash | $33 | $31 | $18 | $20 |
| + Debt | $2 | $23 | $23 | $17 |
| Enterprise Value | -$13 | $7 | $12 | $7 |
| Revenue | $14 | $15 | $18 | $16 |
| % Growth | -8.2% | -18% | 13.8% | – |
| Gross Profit | $9 | $10 | $13 | $11 |
| % Margin | 66.1% | 67.8% | 69.4% | 66.5% |
| EBITDA | $3 | -$17 | $6 | $3 |
| % Margin | 23.6% | -115.1% | 32.7% | 16.2% |
| Net Income | $2 | -$20 | $4 | $1 |
| % Margin | 14.1% | -130.9% | 21.6% | 4.9% |
| EPS Diluted | -0.08 | -2.92 | 0.21 | -0.26 |
| % Growth | 97.3% | -1,490.5% | 180.8% | – |
| Operating Cash Flow | -$1 | $3 | -$6 | $3 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$1 | $3 | -$7 | $3 |